Become
a shareholder
of Five Lives !
50 million people are affected by Alzheimer's disease, with no available treatment to date. Invest in Five Lives and help revolutionize dementia treatment with the first clinically validated therapeutic applications. Join CNP Assurances, 50 Partners and Family Ventures to accelerate product and commercial development of an innovation that improves quality of life.
To proceed further in the investment process, we recommend using the Chrome translator extension directly on the Sowefund website (which is in French), or calling an advisor directly for guidance through the process at 07 45 88 03 46.
Five Lives in figures
What is Five Lives?
To support the 50 million people affected by Alzheimer's without any available treatment, FIVE LIVES is revolutionizing brain health with the first clinically validated therapeutic applications to prevent and treat cognitive decline:
- Five Lives (Prevention): for adults 50+ looking to maintain their brain health
- Five Lives Care (Treatment): for people living with memory difficulties or Mild Cognitive Impairment (MCI)
The only solution combining a comprehensive multi-domain approach: engaging 15-30 minute sessions combining adapted physical exercise, cognitive training, nutrition, sleep and social connection. Scientific research proves it: such an approach can gain years of healthy life, regardless of genetic risk.
Our innovation is based on:
- Collaboration with the University of Oxford and several memory centers in France and the United Kingdom
- The methodology of the FINGER study (world reference in Alzheimer's prevention)
- Support from the ‘Vaincre Alzheimer’ Foundation in France
We are currently finalizing a €2M+ funding round (€1.7M already secured from CNP Assurances, 50 Partners, Family Ventures) to:
- Accelerate our commercial expansion in France and Europe
- Enhance product experience and therapeutic efficacy
- Obtain reimbursement as a digital therapeutic
Why invest in Five Lives?
- Advanced clinical validation : A head start on the competition thanks to our ongoing clinical trials: 170 patients, randomized controlled study with Oxford University, APHP Broca (Paris) and La Timone (Marseille). Goal: reimbursement and medical prescription in France, then Belgium, Switzerland, Germany.
- European Leader in a high-growth market: A sector driven by a health emergency (50 million people affected by Alzheimer's worldwide, 150 million expected by 2050) and prestigious clinical and commercial partnerships.
- Diversified B2B2C revenue model, international with strong growth potential: Prescription by clinicians (out-of-pocket pending reimbursement), Big Pharma (digital support for new anti-Alzheimer therapies in countries where they are prescribed), Health Insurers (prevention and healthy aging programs for 50+ policyholders). Ambition: €1M+ in 2026 -> €100M and 500K patients treated by 2030.
- A real impact on people's lives : "Diagnosed with Alzheimer's disease 5 years ago, I use Five Lives Care daily. The exercises are stimulating without being frustrating, and I feel more confident in my daily life." Jean-François - 80 years old, Five Lives Care user
The Five Lives Team
CEO Successful entrepreneur: founder of Peak, the world's first brain training app (60 million users). Sold to Lagardère Group in 2016.
COO Expert in business development and operations. Specialized in medical applications and certified digital health devices.
Investing in Five Lives,
how does it work?
Create your account on our partner investment platform Sowefund
Get early access to investment opportunities
Choose the amount you wish to invest (starting at €1,000) and become a shareholder.
They support Five Lives
CNP Assurances36 million policyholders worldwide - France's #1 mortgage insurance and #2 life insurance - Investment via Open CNP (portfolio: Alan, Lydia, Alice & Bob) - Strong commitment to Health Prevention. 
50 PartnersSpecialized health and impact fund.
SpeedinvestFund specializing in AI and new technologies.
Prof. Ivan KOYCHEVChief Medical Officer Five Lives, Clinical Neuropsychiatrist, world reference in cognitive disorders and digital therapies - Associate Professor Imperial College & Oxford University.
Prof. Olivier HANONMedical and Scientific Advisor to FIVE LIVES, Professor of Cardiology-Geriatrics, Head of Geriatrics Department, Broca Hospital (APHP), President of Gérond'If (Île-de-France gerontology hub), Five Lives' main clinical partner and CRO.
Prof. Pierre Krolak-SalmonMedical and Scientific Advisor to FIVE LIVES, Medical Director EMEIS Group, Professor of Neurology & Geriatrics, World specialist in neurodegenerative diseases.
AllianzFirst European insurer to have deployed Five Lives in production for its 50+ policyholders (via the ANCRE association and Allianz Accelerator).
Big PharmaPharma: Industry partners. Biogen, Eli Lilly, Servier: Contracts signed for €300K+ on digital support for Alzheimer's treatments being deployed (international).
Fondation Vaincre AlzheimerTogether against Alzheimer's. €1 per monthly subscription to Five Lives / Five Lives Care donated to the ‘Vaincre Alzheimer’ Foundation in France.Our investment thesis:
select the best tech & impact deals
1% of selected deals
A team of analysts with expertise in venture capital
Due diligence recognized by market experts The leading crowdfunding
plateform !
A community of investors committed to the major transitions taking place in our world.
160,000investorsMillions of euros raised to boost the growth of innovative companies.
120M€raisedA trusted partner to France's most ambitious entrepreneurs for 10 years.
+140fundraising